Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides.

What does this source report?

The later platform paper studies suppressive cyclic derivatives. Opposing experimental effects do not establish a shared receptor or clinical interchangeability.

Population and setting

See original report; human, animal and laboratory components must be distinguished.

Evidence type

Animal / experimental

Preparation

Preparation-specific research; no equivalence inferred

Source language

eng

Title provenance

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

What are the limitations?

• Full methods, preparation identity and risk of bias require appraisal.
• Related publications may share experiments; source count is not independent-study count.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Source access and review scope

Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.

Recorded source-check date: 2026-10-02. This date does not imply a completed systematic review.

Open original source or index record ↗

DOI: 10.1016/j.intimp.2020.106185

Cite and trace this record

Original source: Deigin V, Ksenofontova O, Yatskin O, Goryacheva A, Ignatova A, Feofanov A, Ivanov V.. Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides. International immunopharmacology 2020.

Molekul research summary: https://molekul.io/research/gaps-32058926. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles